TITLE

Russell charts new path

AUTHOR(S)
Breitstein, Joanna
PUB. DATE
January 2009
SOURCE
Pharmaceutical Representative;Jan2009, Vol. 39 Issue 1, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports updates related to Shire PLC. The Human Genetic Therapies (HGT) business of the company has grown and diversified both in product portfolio and geographic reach for the past three years. The company's sales for the third quarter of 2008 has increased as a result of the strong market performance of its generic drugs. The company has also launched its potential plans for 2008 to 2015, including heavy focus on orphan drugs and Shire's litany of production deals.
ACCESSION #
36094425

 

Related Articles

  • Shire gets third generic threat to Adderall.  // PharmaWatch: CNS;January 2005, Vol. 4 Issue 1, p12 

    Reports on the reduction in the shares in Shire Pharmaceuticals Inc. after the company received notice of the third generic challenge to its Adderall XR drug from Colony Pharmaceuticals Inc. Percentage of the reduction in shares; Submission of abbreviated new drug application for amphetamine...

  • COMPANY SPOTLIGHT - Shire plc.  // PharmaWatch: CNS;Jul2009, Vol. 8 Issue 7, p27 

    The article offers information on pharmaceutical company Shire Pharmaceuticals Group PLC. It notes that Shire reported new findings on Intuniv extended release wherein it showed significant symptom improvement in attention deficit hyperactivity disorder (ADHD). It mentions that Shire focuses its...

  • Think Small. Grow Big. Breitstein, Joanna // Pharmaceutical Executive;Jul2004, Vol. 24 Issue 7, p52 

    Focuses on the business decisions made by Matthew Emmens as CEO of Shire Pharmaceuticals Group. Relocation from Philadelphia to Wayne, Pennsylvania; Shire's revenues in 2003; Consolidation activities of Shire under Rolf Stahel as CEO; Founding history; Problems which arose as consequence of...

  • COMPANY SPOTLIGHT - Shire Pharmaceuticals Group plc.  // PharmaWatch: CNS;May 2004, Vol. 3 Issue 5, p18 

    Presents a corporate profile of pharmaceutical firm, Shire Pharmaceuticals Group PLC in Great Britain. Ability of the company to develop therapeutics for central nervous system disorders; Ownership of exclusive marketing rights for its several patented products; Percentage of increase for its...

  • Shire Buys Orphan-Drug Firm. Investor's Business Daily // Investors Business Daily;11/3/2015, pA01 

    9 The Irish drugmaker agreed to pay $5.9 bil cash, or $37.30 a share, for

  • Vyvanse prepares to lead ADHD class. McGuire, Stephen // Medical Marketing & Media;Aug2007, Vol. 42 Issue 8, p24 

    The article reports on the move of Shire PLC to gather 560 sales personnel on the launching of its attention-deficit hyperactivity disorder (ADHD) drug Vyvanse. According to Matthew Cabrey, Shire's spokesman, the Vyvanse sales team is comprised of individual who have experienced selling other...

  • Shire Pharmaceuticals Group, PLC SWOT Analysis.  // Shire Pharmaceuticals Group, PLC SWOT Analysis;August 2003, p1 

    Presents an overview of Shire Pharmaceuticals Group PLC, a pharmaceutical company which focuses on four therapeutic areas, namely central nervous system disorders, gastrointestinal, oncology and anti-infectives. Company overview, including revenues generated in fiscal year 2002 and location of...

  • Company Overview.  // Shire Pharmaceuticals Group, PLC SWOT Analysis;August 2003, p4 

    Presents an overview of Shire Pharmaceuticals Group PLC, a pharmaceutical company which focuses on four therapeutic areas, namely central nervous system disorders, gastrointestinal, oncology and anti-infectives. Revenues generated in fiscal year 2002; Location of the company's headquarters.

  • Key Facts.  // Shire Pharmaceuticals Group, PLC SWOT Analysis;August 2003, p4 

    Presents key facts about Shire Pharmaceuticals Group PLC, a pharmaceutical company which focuses on four therapeutic areas, namely central nervous system disorders, gastrointestinal, oncology and anti-infectives. Address and contact information; Revenues and financial year end data; Number of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics